Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (April 2023)
19 slides from Moleculin Biotech's investor presentation, Apr 3, 2023
Slide 1: Moleculin
od 3 MOLECULIN We PN te
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, inchiding statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe;
Slide 3: Investment Highlights
Investment Highlights J % Annamycin - Advancing growing pipeline of clinical programs rene of highly Pipeline Expansion Pe al 7
Slide 4: Priority Development Pipeline
Priority Development Pipeline PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE2 UPCOMING MILESTONES. Annamycin WP1122 GBM, Other T tric Brain Tumors ding DPIG WP1066 Bimovecuun
Slide 5: Additional Development Pipeline
Additional Development Pipeline ad Additional Follow-on Opportunities Provide Potential for Significant Upside PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE 2 UPCOMING MILESTONES, ‘Annamycin or MangPareros Radiation wp1122 WPL122, WP1096, em wp1097 Trop
Slide 6: Management Team with Proven Executional Expertise
Management Team with Proven Executional Expertise
Slide 7: Leveraging the Brightest Scientific Minds
Leveraging the Brightest Scientific Minds 4 HEMATOLOGY IROLOGY PANCREATI ese, MD Hongbo Zhai, MO 2-Farber UCop Wy puke University Sthool of Medine
Slide 8: Annamycin: Potential to Be an Effective Treatment Across Multiple Oncology Indications
Annamycin: Potential to Be an Effective Treatment Across Multiple Oncology Indications Clinical Highlights Demonstrated 60% ORR in Phase 1 in TST; Phase 1b portion commenced Announced RP2D and efficacy of 80% ORR in last cohort of single agent AML trial; Received approval in Italy to conduct Phase 1
Slide 9: Annamycin: Next Generation Anthracycline
Annamycin Next Generation Anthracycline % of Mice with Heart Lesions Demonstrated to Be Non-Cardiotoxict Ability to overcome multi-drug resistance Organotrophic properties (e.g. >30x greater accumulation in lungs than doxorubicin) Potent topoisomerase-II poison with a wider therapeutic window than d
Slide 10: Annamycin: Phase 1b/2 Trial for STS Lung Mets
Annamycin Ongoing Phase 2 Portion of Phase 1b/2 Trial for Treatment of STS Lung Mets U.S. Multi-Center, Open-Label, Dose Escalation Study Demonstrated a Preliminary Response of 67% (4 of 6) of Subjects Showing Stable Disease Through 2 or More Cycles, One Subject Continuing with the Study Drug 14 of
Slide 11: Annamycin: Phase 1b/2 Combination Trial for R/R AML
Annamycin Phase 1b/2 Combination Trial for Treatment of Relapsed or Refractory (R/R) AML Evaluating Annamycin in Combination with Cytarabine (Ara-C) 80% Overall Respons: RR) in the 5 Subjects Treated with RP2Din t e Final Cohort 3 Subjects Achieved Pa 1 Achieved Complete Response with Incomple' ry o
Slide 12: Annamycin: AML Clinical Benefit
Annomycin AML Clinical Benefit? / [) R/R AML patients treated in both US and EU trials 22 Best overall response rate in 240 mg? cohort (including a CRi that qualified for curative BMT) 80% MOLECULIN Patients in Moleculin’s clinical trials taken above the lifetime maximum anthracycline dose establish
Slide 13: The Full Annamycin Opportunity
The Full Annamycin Opportunity Potential for Significant Upside ‘a TNECLung — 60k 67k RCCLure — 67K Endometrial Lung ___ 13,500 Initial Annamycin 20,000 104K Target indications} Acute Myelcia 5 Colorectal Br Acie Potential Annamycin es TOTALINCIDENCE Expansion Indications poe TOTALINCIDENCE ae tiall
Slide 14: WP1066: Flagship Immune/Transcription Modulator
WwP1066 Flagship Immune/Transcription Modulator Y Expect to report topline results from investigator- initiated Phase 1 study in pediatric brain tumors in 2023 Received IND clearance from the FDA to conduct a Phase 1 study in GBM in adults Ongoing discussions with multiple academic institutions to i
Slide 15: WP1122 Portfolio
WP1122 Portfolio Metabolism/Glycosylation Inhibitor Key Highlights dg f licasn dco edb it proptes ‘Targets glycolysis and glycosylation; limits viral infectivity and replication (Open IND to initiate Phase 1 for treatment of GBM Clinical Highlights Concluded Phase 1a overlapping SAD and MAD trial wi
Slide 16: Financial Snapshot
Financial Snapshot Nasdaq: MBRX Strong Cash Position Funds Operations Beyond Mid-2024! ~$43.1M ~28.6M ~68.8K Cash Shares 3 Month Avg. Balance? Outstanding* Volume?
Slide 17: Multiple Milestones And Key Data Readouts
Multiple Milestones And Key Data Readouts Expected In 2023 C ) AML AML AML STS (US) STS (EU) oe “6 “ee Commence dosing Publish CSR MB-106 Phase 2 Phase 1b/2 in Phase 1b/2Ara-C for MB-105 cohort data _—interimdata__ interim data combination study Phase 1 results WP1122/ Arenaviruses GBM Pediatric Bra
Slide 18: Investment Summary
Investment Summary Annamycin with al th Phase 1 studies?, four ongoing or pot capable of prod: ita 1 future Pipeline Expansion Potential expat Global Network Sufficient capital to fund operations beyond mid-20241 1d programs fuel p al high-value ible pipeline ations 18
Slide 19: Thank You!
Thank You! 0 8, coo MOLECULIN Spy
Moleculin Biotech — Investor Presentation (April 2023) on 6ix